TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: successful penetration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: successful intercourse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: net urine output (nUOP)/24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24-hour time-average glucose values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: postprandial triglyceride excursions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in lesion counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in sebum production
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of walking velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of walking capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postural sway frequency analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Workload as measured by NASA-TLX
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Discomfort as measured by BPD
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: total mean score of communication skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in episodes of urge urinary incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: time for the task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total error score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: spatial paths and velocity of forceps
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: care management contacts
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Vaccine efficacy against severe RVGE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vaccine efficacy against all-cause severe GE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean ablation times
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Reported genital symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Genital examination findings
Endpoint domain: Adverse events/effects
Primary endpoint: Product acceptability
Endpoint domain: Adverse events/effects
Primary endpoint: CHF hospital admissions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of patients on target vasodilator therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self-rated nightmare frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dice similarity coefficient for segmented tissues
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative HbA1c reduction from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Probability of having a high anxiety state
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: IA territorial concordance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Supine time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decrease in aortic valve area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: lower AD rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decreased albumin excretion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Risk of progression to diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Risk of death without diabetes
Endpoint domain: Mortality/survival
Primary endpoint: Transition to non-diabetic status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Isokinetic plantar flexion strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Social avoidance
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: CCS angina score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fear of the dentist
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Perceived time needed for treatment
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: complete abortion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Plasma endothelin-1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum plasma concentrations of active ingredients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of adverse events (rash)
Endpoint domain: Adverse events/effects
Primary endpoint: CD4 T cell reconstitution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Arm skin temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Leg skin temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SA correction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physician performance at contextualizing care
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gastric ulcer-free patients percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Reduction in circumferential ITC area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: endothelium-dependent microvascular vasodilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Functional outcome (modified Rankin Scale)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of EGFR mutations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative incidence rates for prostate cancer
Endpoint domain: Mortality/survival
Primary endpoint: Cumulative mortality rates from prostate cancer
Endpoint domain: Mortality/survival
Primary endpoint: HCO(3) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: pCO(2) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Decrease in serum creatinine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Increase in creatinine clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Survival until day 15
Endpoint domain: Mortality/survival
Primary endpoint: Frequency of vasovagal reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Pain evaluated on a visual analog scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle mass (ALM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle strength (MVC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle power (PP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tumor line classification accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom from symptomatic AF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Freedom from recurrent atrial arrhythmia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean QoL score improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Achieving NCEP ATP III LDL‐C goals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Lowering LDL‐C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Increasing HDL‐C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Whole body protein net balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peak forced expiratory volume in 1 second
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: performance and satisfaction with performance ratings on untrained goals
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Normalization of brain activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean improvement in HAD-D score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients considering themselves to feel better
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Increase in GAF score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resistance of LDL to oxidation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AIA positive status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: percentage of people newly developing AIA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: ≥4‐fold increase in AIA titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of contrast agent-induced nephropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: BALF TNF-alpha concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: BALF IL-8 concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of positive findings with definitive diagnoses of brain death
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: self-reported symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment preferences expressed in living wills
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in end-systolic volume index (ESVI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Hb decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: depression risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain relief during walking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exacerbation of acute knee pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percent decrease in mortality
Endpoint domain: Mortality/survival
Primary endpoint: Incidence rate of adverse events leading to discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Clinically meaningful improvements in signs and symptoms of RA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average steps walked per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lower carbon monoxide levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Less withdrawal severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Less smoking of usual brand cigarettes during treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tibial dorsal slope
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Leg axis alignment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ulcer remission probability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: percentage reduction in weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cuff Pressure (CP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volume of air injected into the cuff
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Air leakage
Endpoint domain: Adverse events/effects
Primary endpoint: Cure rate of stress urinary incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of patients with mucositis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clearance of racemic ketorolac
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Terminal half-life of S(‐)‐ketorolac
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apparent volume of distribution of S(‐) enantiomer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction in negative affect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduced depressive symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak deoxygenated hemoglobin+myoglobin concentration changes (Δ[deoxy(Hb+Mb)])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Circulating endothelial progenitor cells (EPCs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Infarct size at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Immune response interference
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Chlorzoxazone area under the concentration-time curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time taken for IUD insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pre-sleep saliva melatonin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: 42 day cure rates adjusted for reinfection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical beneficial rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: effective rate in relieving pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: life functioning
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: AUC(0-72) of atorvastatin lactone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Elimination half-life of atorvastatin acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-72) of active HMG-CoA reductase inhibitors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: External rotation improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Clinical outcomes improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total sum score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: dribbling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in MADRS-S and BSA-S scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in depression and anxiety scores
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of PONV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accommodative amplitude and range
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Elicitation of HIV-related factors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Preference for R/L IKDC‐SKF
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean difference in IKDC‐SKF scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of PCP
Endpoint domain: Adverse events/effects
Primary endpoint: GUSTO severe/moderate bleeding within 120 hr
Endpoint domain: Adverse events/effects
Primary endpoint: Hyper/hypopigmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Induration/fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Range of knee flexion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of postoperative nausea and emesis
Endpoint domain: Adverse events/effects
Primary endpoint: Intravenous hypotension incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Systolic blood pressure change during hemodialysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximal treadmill walking distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WIQ distance score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: SF‐36 physical summary score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: seizure rate reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: overall pathological response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WHO grade 3-4 neutropenia
Endpoint domain: Adverse events/effects
Primary endpoint: Urinary incontinence scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Increase in motivational aspects
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: 3-year survival and success rate
Endpoint domain: Mortality/survival
Primary endpoint: clinical attachment level values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of survival
Endpoint domain: Mortality/survival
Primary endpoint: Good outcome (GOS‐E score >4) at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: adherence rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: systemic vascular resistance during tilt
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: upright blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in weapon carrying
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain in grip
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in glucose response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in insulin response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Drop in hemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Full Scale IQ
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Digit Span
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Block Design
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ALT levels post-surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: TBil levels post-surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Fasting and/or postprandial colonic tone and/or compliance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Contraceptive knowledge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Correct contraceptive choice
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Contraceptive usage
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Contraceptive continuation rates
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean image quality per segment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of uninterpretable segments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 90-day readmissions
Endpoint domain: Mortality/survival
Primary endpoint: Adjusted healthcare costs at 30 days
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Adjusted healthcare costs at 90 days
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Incidence of non-fatal reinfarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Blood Albumin Concentration (BAC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Half-life of exogenous albumin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Linkage to HIV care
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prostate volumes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum UFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression of radiologic damage
Endpoint domain: Adverse events/effects
Primary endpoint: Mean volume of thyroid nodules
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ME resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes